Vabysmo was generally well-tolerated and no new safety signal of this combination were observed.
'I am very pleased that Vabysmo demonstrates good vision improvement for the first time in Japanese in clinical study for angioid streaks, a rare disease with no approved drugs in
The data will be submitted to health authorities in
About angioid streaks
Angioid streaks is a disease characterized by a crack in a part of retina, causing-discoloration (pigmented streak) of the fundus. The disease is often asymptomatic, and when choroidal neovascularization extends to the macula region of the fundus, it causes symptoms such as decreased or distorted vision. People with neovascularization have a poor prognosis, but conventional treatments such as surgery and laser are not sufficiently effective, and new treatment options are needed. The number of patients in
About NIHONBASHI study
NIHONBASHI study is a multicenter, single-arm phase III study in
About Vabysmo
Vabysmo is the first bispecific antibody approved in the ophthalmology field.3,4 It targets and inhibits two signaling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation5,6 By blocking pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilize blood vessels.5,6 Vabysmo is approved in more than 90 countries around the world, including
Contact:
Tel: +81-3-3273-0881
Email: pr@chugai-pharm.co.jp
Tel: +81-3-3273-0554
Email: ir@chugai-pharm.co.jp
(C) 2024 Electronic News Publishing, source